IP Library › Granted Patent US 12,310,951
Granted Patent B2
US 12,310,951 · App. 18/440,652 · Granted May 27, 2025

Methods of administering anti-fibrotic therapy

Inventors: Lin Pan (San Francisco, CA); Dorothy Sze-Wing Cheung (San Francisco, CA); Jeffrey Mark Harris (San Francisco, CA); Indiana Strombom (San Francisco, CA)
Assignee: Genentech, Inc.
A61K31/437A61K31/4439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,951
App. No.
18/440,652
Granted
May 27, 2025
Kind
B2
Abstract

The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.

Claims (2)

1. A method of administering Compound I to treat a subject suffering from a fibrotic disorder said method comprising

increasing the maximal plasma concentration (C max ) or the extent of absorption (AUC 0-t or AUC 0-∞ ) of Compound I wherein the C max or AUC of Compound I with food is increased compared to the C max or AUC of the same amount of Compound I administered without food.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: INTERMUNE, INC.
To: GENENTECH, INC.
Reel/Frame 068698/0708 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2024
From: PAN, LIN; CHEUNG, DOROTHY SZE-WING; HARRIS, JEFFREY MARK; STROMBOM, INDIANA
To: GENENTECH, INC.
Reel/Frame 066457/0911 →
Continuity (5)
Continuation 17528537 · Nov 17, 2021
Division 16465015
Provisional Application 62432425 · Dec 9, 2016
Provisional Application 62428163 · Nov 30, 2016
Related Publication 20240197693A1 · Jun 20, 2024
References Cited (27)
US 10376497B2 · Buckman et al. · 2019 [cited by applicant]
US 11207304B2 · Pan et al. · 2021 [cited by applicant]
US 11925624B2 · Pan et al. · 2024 [cited by applicant]
CN 104822687A · 2015 [cited by applicant]
WO WO2014055548A1 · 2014 [cited by applicant]
WO 2015153683 · 2015 [cited by applicant]
WO WO2015153683A1 · 2015 [cited by applicant]
“Clinical Pharmacy and Pharmacotherapeutics”, edited by Liang Xuzhong et al., Jilin Science and Technology Press, p. 202 (Jun. 2016). [cited by applicant]
“Diagnosis, Treatment and Medication Guidance of Respiratory Diseases”, edited by Xiong Bin, et al., Xi'an Jiaotong University Press, p. 286 (Oct. 2015). [cited by applicant]
“Gastric Acid”, Wikipedia entry, 5 pp. (May 2015). [cited by applicant]
“Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies”, Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Resear… [cited by applicant]
“Pathological Etiology”, edited by Shen Xiaojun et al., Henan Science and Technology Press, p. 290 (Feb. 2009). [cited by applicant]
Adithan, Food and drug bioavailability, Indian J. Med. Res., 121(5):631-3 (May 2005). [cited by applicant]
Arnold et al., Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets, Bone, 10(6):401-7 (1989). [cited by applicant]
Barton et al., Endothelin: 20 years from discovery to therapy, Can. J. Physiol. Pharmacol., 86(8):485-98 (2008). [cited by applicant]
Hino et al., Drug interaction (34, Drug interaction of food and medicine), Journal of Okayama Medical Association, 127:245-9 (2015). [cited by applicant]
International Application No. PCT/US2017/063549, International Search Report and Written Opinion, dated Apr. 5, 2018. [cited by applicant]
Japanese Patent Application No. 2019-524383, Notice of Reasons for Rejection, mailed Sep. 3, 2021. [cited by applicant]
Kitamura et al., Drug Side Effects and Interactions, OtoRhinoLaryngology, Tokyo, 1997, vol. 40, No. 3, pp. 347-352 (99-104). [cited by applicant]
Kowalczyk et al., The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis, Arch. Immunol. Ther. Exp., 63:41-52 (2015). [cited by applicant]
National Kidney Foundation, K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease (2002). [cited by applicant]
Nawa et al., Drug interaction (15. combination with H2-receptor antagonist, Journal of Okayama Medical Association, 2009, vol. 121, pp. 49-51. [cited by applicant]
Winstanley et al., The effects of food on drug bioavailability, Br. J. Clin. Pharmacol., 28(6):621-8 (Dec. 1989). [cited by applicant]
Anonimous, “Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function” European Medicines Agency Science Medicine Health: 1-15 (Apr. 20, 2014). [cited by applicant]
Doogue et al., “Drug Dosing in Renal Disease” Clin Biochem Rev 32:69-73 (May 1, 2011). [cited by applicant]
Munar et al., “Drug Dosing Adjustments in Patients with Chronic Kidney Disease” American Family Physician 75(10):1487-1496 (Jan. 1, 2007). [cited by applicant]
Swan et al., “Conferences and Reviews Drug Dosing Guidelines in Patients With Renal Failure” West J Med 156:633-638 (Jun. 1, 1992). [cited by applicant]